IDIOPATHIC HYPERCALCIURIA. DIAGNOSIS AND TREATMENT


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Most patients with idiopathic hypercalciuria and calcium nephrolithiasis have a family history of the disease. Idiopathic hypercalciuria is a metabolic abnormality with various causes and developmental pathways. The systematic review describes specific mutations associated with idiopathic hypercalciuria and nephrolithiasis. Detection of these mutations may provide a better understanding of the pathogenesis of this heterogeneous disease and personalize patient management depending on the detected polymorphisms. A promising treatment option for a mutation in the vitamin D receptor gene is thiazide diuretics in combination with bisphosphonates. Among bisphosphonates, the drug of choice which has been most strongly supported by research evidence is alendronate.

Full Text

Restricted Access

About the authors

Yu. V Olefir

I.M. Sechenov First MSMU (Sechenov University); Scientific Centre for Expert Evaluation of Medicinal Products

Professor of the Urological Department Moscow, Russia

A. N Yavorskii

Scientific Centre for Expert Evaluation of Medicinal Products

Email: 200-31-11@mail.ru
Professor Moscow, Russia

D. V Butnaru

I.M. Sechenov First MSMU (Sechenov University)

Email: butnaru_dv@mail.ru
MD, PhD, Assisted Professor of the Urological Department Moscow, Russia

O. V Shatalova

Volgograd State Medical University of the Ministry of Health of Russia

PhD, assistant of the department for Clinical Pharmacology and Intensive Therapy with Clinical Pharmacology and Clinical Allergology, College of Advanced Medical Studies Volgograd, Russia

V. S Gorbatenko

Volgograd State Medical University of the Ministry of Health of Russia

PhD, assistant of the department for Clinical Pharmacology and Intensive Therapy with Clinical Pharmacology and Clinical Allergology Volgograd, Russia

A. S Gerasimenko

Volgograd State Medical University of the Ministry of Health of Russia

assistant of the department for Clinical Pharmacology and Intensive Therapy with Clinical Pharmacology and Clinical Allergology, College of Advanced Medical Studies Volgograd, Russia

References

  1. Аляев Ю.Г. Мочекаменная болезнь: современные методы диагностики и лечения: руководство. М.: ГЭОТАР-Медиа; 2010. 224 с.
  2. Scales C.D., Smith A.C., Hanley J.M. Prevalence of kidney stones in United States. Eur. Urol. 2012;62:160-165.
  3. Romero V., Akpinar H., Assimos D.G. Kidney Stones: A Global Picture of Prevalence, Incidence, and Associated Risk Factors. Rev Urol. 2010;12(2-3):e86-96.
  4. Trinchieri A., Montanari E. Prevalence of renal uric acid stones in the adult. Urolithiasis. 2017.
  5. Аляев. Ю.Г. Мочекаменная болезнь. Современные методы диагностики и лечения. 2012. С. 38-42.
  6. Worcester E.M., Coe F.L. Nephrolithiasis. Prim. Care. 2008;35:369-391.
  7. Worcester E.M., Coe F.L. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008;28:120-132.
  8. Monico S.G., Milliner D.S. Genetic Determinants of Urolithiasis. Nat Rev Nephrol. 2011;20:151-162.
  9. Park S., Pearle M.S. Pathophysiology and management of calcium stones. Urol Clin N Am. 2007;31:323-334.
  10. Nordin B.E.C., Peacock M., Wilkinson R. Hypercalciuria and calcium stone disease. Clinics in endocrinology and metabolism. 1972;1:169-183.
  11. Pak C.Y., Britton F., Peterson R., Ward D., Northcutt C., Breslau N.A., McGuire J., Sakhaee K., Bush S., Nicar M., Norman D.A., Peters P. Ambulatory evaluation of nephrolithiasis: classification, clinical presentation and diagnostic criteria. Am J Med. 1980;69(1):19-30.
  12. Pak C.Y., Oata M., Lawrence E.C., Snyder W. The hypercalciurias: causes, parathyroid functions and diagnostic criteria. J Clin Invest. 1974;54:387-400.
  13. Peacock M., Nordin B.E.C. Tubular reabsorption of calcium in normal and hypercalciuric subjects. J Clin Pathol. 1968;21:353-358.
  14. Pak C.Y.C., Pearle M.S., Sakhaee K. Detection ofabsorptive hypercalciuria type I without the oral calcium load test. J Urol. 2011;185:915-919.
  15. Pak C.Y.C., Pearle, M.S., Sakhaee K. Evidence for metabolic origin of absorptive hypercalciuria Type II. Urol Res. 2011;39:147-152.
  16. Dominguez Dominguez M., Reina Ruiz C., Blasco Hernandez P., Espinosa Olmedo J., Conde Sanchez J.M., Vega Toro P., Garcia Pérez M. Absorptive hypercalciuria type III or caused by renal loss of phosphates. Actas Urol Esp. 2000;24:219-222.
  17. Dinour D., Beckerman P., Ganon L., Tordjman K., Eisenstein Z., Holtzman E.J. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol. 2013;190:552-557.
  18. Nesterova G., Malicdan M.C., Yasuda K., Sakaki T., Vilboux T., Ciccone C., Horst R., Huang Y., Golas G., Introne W., Huizing M., Adams D., Boerkoel C.F., Collins M.T., Gahl W.A. 1,25(OH)iD-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis. Clin J Am Soc Nephrol. 2013;8:649-657.
  19. Maierhofer W.J., Gray R.W., Adams N.D. Bone resorption stimulated by elevated serum 1,25(OH)2-vitamin D concentrations in healthy men. Kidney Int. 1983;24:555-560.
  20. Adams N.D., Gray R.W., Lemann J. Jr., Cheung H.S. Effects of calcitriol administration on calcium metabolism in healthy men. Kidney Int. 1982;21:90-97.
  21. Coe F.L., Parks J.H., Evan A.P. et al. Pathogenesis and Treatment of Nephrolithiasis. The Kidney. chap. 68. Elsevier, Inc. 2007. p. 1945-1977.
  22. Hoenderop J.G., Nilius B., Bindels R.J.M. Calcium absorption across epithelia. Physiol Rev. 2005;85:373-422.
  23. Kaplan R.A., Haussler M.R., Deftos L.J., Bone H., Pak C.Y. The role of 1 alpha 25 dihydroxyvitamin D in the mediation ofintestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest. 1977;59:756-760.
  24. Christakos S., Dhawan P., Porta A., Mady L.J., Seth T. Vitamin D and intestinal calcium absorption. Mol Cell Endocrinol. 2011;347:25-29.
  25. Broadus A.E., Insogna K.L., Lang R., Mallette L.E., Oren D.A., Gertner J.M., Kliger A.S., Ellison A.F. A consideration of the hormonal basis and phosphate leak hypothesis of absorptive hypercalciuria. J Clin Endocrinol Metab. 1984;58:161-169.
  26. Insogna K.L., Broadus A.E., Dreyer B.E., Ellison A.F., Gertner J.M. Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. J Clin Endocrinol Metab. 1985;61:490-495.
  27. Breslau N.A., Preminger G.M., Adams B.V. et al. Use of ketoconazole to probe the pathogenetic importance of 1,25-dihydroxyvitamin D in absorptive hypercalciuria. J Clin Endocrinol Metab. 1992;75:1446-1452.
  28. Barilla D.E., Zerwekh J., Pak C.Y.C. A critical evaluation of the role of phosphate in the pathogenesis of absorptive hypercalciuria. Miner Electrolyte Metab. 1979;2:302-309.
  29. Zerwekh J.E., Pak C.Y., Kaplan R.A., McGuire J.L., Upchurch K., Breslau N., Johnson R. Jr. Pathogenetic role of 1,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J Clin Endocrinol Metab. 1980;51:381-386.
  30. Bushinsky D.A., Frick K.K., Nehrke K. Genetic hypercalciuric stone-forming rats. Curr Opin Nephrol Hypertens. 2006;15:403-418.
  31. Bushinsky D.A., Grynpas M.D., Nilsson E.L., Nakagawa Y., Coe F.L. Stone formation in genetic hypercalciuric rats. Kidney Int. 1995;48:1705-1713.
  32. Bushinsky D.A., Asplin J.R., Grynpas M.D., Evan A.P., Parker W.R., Alexander K.M., Coe F.L. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int. 2002;61:975-987.
  33. Li X.Q., Tembe V., Horwitz G.M., Bushinsky D.A., Favus M.J. Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption. J Clin Invest. 1993;391:661-667.
  34. Tsuruoka S., Bushinsky D.A., Schwartz G.J. Defective renal calcium reabsorption in genetic hypercalciuric rats. Kidney Int. 1997 ;51:1540- 1547.
  35. Yao J., Kathpalia P., Bushinsky D.A. et al. Hyperresponsiveness ofVitamin D Receptor Gene Expression to 1,25-Dihydroxyvitamin D3. A New Characteristic of Genetic Hypercalciuric Stone-forming Rats. J Clin Invest. 1998;101:2223-2232.
  36. Scott P., Ouimet D., Valiquette L., Guay G., Proulx Y., Trouvé M.L., Gagnon B., Bonnardeaux A. Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc. 1999;10:1007-1013.
  37. Lin Y., Mao Q., Zheng X., Chen H., Yang K., Xie L. Vitamin D receptor genetic polymorphisms and the risk of urolithiasis: a meta-analysis. Urol Int. 2011;86:249-255.
  38. Zhang P., Nie W., Jianget H. Effects of vitamin D receptor polymorphisms on urolithiasis risk: a meta-analysis. BMC Medical Genetics. 2013;14:104.
  39. Аполихин О.И., Сивков А.В., Константинова О.В., Сломинский П.А., Тупицына Т.В., Калиниченко Д.Н. Поиск полиморфных вариантов кандидатных генов мочекаменной болезни в российской популяции. Клиническая и экспериментальная урология. 2013;3:56-60.
  40. Mohammadi Z., Fayyazbakhsh F., Ebrahimi M., Amoli M.M., Khashayar P., Dini M., Zadeh R.N., Keshtkar A., Barikani H.R. Association between vitamin D receptor gene polymorphisms (Fok1 and Bsm1) and osteoporosis: a systematic review. J Diab Metab Dis. 2014;13:98.
  41. Rendina D., Mossetti G., Viceconti R., Sorrentino M., Castaldo R., Manno G., Guadagno V., Strazzullo P., Nunziata V. Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients. Urology. 2004;64:833-838.
  42. Reed B.Y., Heller H.J., Gitomer W.L., Pak C.Y. Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. J Clin Endocrinol Metab. 1999;84:3907-3913.
  43. Reed B.Y., Gitomer W.L., Heller H.J., Hsu M.C., Lemke M., Padalino P., Pak C.Y. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab. 2002;87:1476-1485.
  44. Müller D., Hoenderop J.G., Vennekens R., Eggert P., Harangi F., Méhes K., Garcia-Nieto V., Claverie-Martin F., Os C.H., Nilius B., J M Bindels R. Epithelial Ca2+ channel (ECAC1) in autosomal dominant idiopathic hypercalciuria. Nephrol Dial Transplant. 2002;17:1614-1620.
  45. Lusenti T., Nicoli D., Farnetti E. et al. Association analysis of the C923T polymorphism in soluble adenylate cyclase gene in Italian calcium stone formers with idiopathic hypercalciuria. Am Soc Nephrol. 2003(suppl. 14):abstr.
  46. Мирная С.С., Пигарова Е.А., Беляева А.В., Мокрышева Н.Г., Тюльпаков А.Н., Рожинская Л.Я. Роль кальций-чувствительного рецептора в поддержании системы кальциевого гомеостаза. Остеопороз и остеопатии. 2010;3:32-36.
  47. Vezzoli G., Tanini A., Ferrucci L., Soldati L., Bianchin C., Franceschelli F., Malentacchi C., Porfirio B., Adamo D., Terranegra A., Falchetti A., Cusi D., Bianchi G., Brandi M.L. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol. 2002;13:2517-2523.
  48. Vezzoli G., Terranegra A., Arcidiacono T., Biasion R., Coviello D., Syren M.L., Paloschi V., Giannini S., Mignogna G., Rubinacci A., Ferraretto A., Cusi D., Bianchi G., Soldati L. R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int. 2007;71:1155-1162.
  49. Besiroglu H., Sahin S., Otunctemur A., Ozbek E. Calcium-sensing receptor gene polymorphisms in patients with calcium urolithiasis: a systematic review. Renal Failure. 2014;36:1187-1192.
  50. Na T., Peng J.B. TRPV5: a Ca2+ channel for the finetuning of Ca2+ reabsorption. Springer. Handbook of Experimental Pharmacology. 2014;222:321-357.
  51. Suzuki Y., Pasch A., Bonny O., Mohaupt M.G., Hediger M.A., Frey F.J. Gain-of-function haplotype in the epithelial calcium channel TRPV6 is a risk factor for renal calcium stone formation. Hum Mol Genet. 2008;17:1613-1618.
  52. Renkema K.Y., Lee K., Topala C.N., Goossens M., Houillier P., Bindels R.J., Hoenderop J.G. TRPV5 gene polymorphisms in renal hypercalciuria. Nephrol Dial Transplant. 2009;24:1919-1924.
  53. Khaleel A., Wu M.S., Wong H.S. A Single Nucleotide Polymorphism (rs4236480) in TRPV5 Calcium Channel Gene Is Associated with Stone Multiplicity in Calcium Nephrolithiasis Patients. Mediators Inflamm. 2015;375427:1-7.
  54. Urabe Y., Tanikawa C., Takahashi A., Okada Y., Morizono T., Tsunoda T., Kamatani N., Kohri K., Chayama K., Kubo M., Nakamura Y., Matsuda K. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible Loci at 5q35.3, 7p14.3, and 13q14.1. PLoS Genet. 2012;8(Iss. 3):e1002541.
  55. Dasgupta D., Wee M.J., Reyes M., Li Y., Simm P.J., Sharma A., Schlingmann K.P., JannerM., Biggin A., Lazier J., Gessner M., Chrysis D., Tuchman S., Baluarte H.J., Levine M.A., Tiosano D., Insogna K., Hanley D.A., Carpenter T.O., Ichikawa S., Hoppe B., Konrad M., Sävendahl L., Munns C.F., Lee H., Jüppner H., Bergwitz C. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol. 2014;25:2366-2375.
  56. Schlingmann K.P., Kaufmann M., Weber S., Irwin A., Goos C., John U., Misselwitz J., Klaus G., Kuwertz-Bröking E., Fehrenbach H., Wingen A.M., Güran T., Hoenderop J.G., Bindels R.J., Prosser D.E., Jones G., Konrad M. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365:410-421.
  57. Dauber A., Nguyen T.T., Sochett E., Cole D.E., Horst R., Abrams S.A., Carpenter T.O., Hirschhorn J.N. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab. 2012;97:268-274.
  58. Tebben P.J., Milliner D.S., Horst R.L., Harris P.C., Singh R.J., Wu Y., Foreman J.W., Chelminski P.R., Kumar R. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab. 2012497:423-427.
  59. Thorleifsson G., Holm H., Edvardsson V., Walters G.B., Styrkarsdottir U., Gudbjartsson D.F., Sulem P., Halldorsson B.V., de Vegt F., d'Ancona F.C., den Heijer M., Franzson L., Christiansen C., Alexandersen P., Rafnar T., Kristjansson K., Sigurdsson G., Kiemeney L.A., Bodvarsson M., Indridason O.S., Palsson R., Kong A., Thorsteinsdottir U., Stefansson K. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet. 2009;41:926-930.
  60. Weber S., Schneider L., Peters M., Misselwitz J., Rönnefarth G., Böswald M., Bonzel K.E., Seeman T., Sulâkovâ T., Kuwertz-Bröking E., Gregoric A., Palcoux J.B., Tasic V., Manz F., Schärer K., Seyberth H.W., Konrad M. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol. 2001;12:1872-1881.
  61. Wrong O.M., Norden A.G., Feest T.G. Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM. 1994;87:473-493.
  62. Frymoyer P.A., Scheinman S.J., Dunham P.B., Jones D.B., Hueber P., Schroeder E.T. X-linked recessive nephrolithiasis with renal failure. N Engl J Med. 1991;325:681-686.
  63. Wu F., Reed A.A., Williams S.E., Loh N.Y., Lippiat J.D., Christie P.T., Large O., Bettinelli A., Dillon M.J., Goldraich N.P., Hoppe B., Lhotta K., Loirat C., Malik R., Morel D., Kotanko P., Roussel B., Rubinger D., Schrander-Stumpel C., Serdaroglu E., Nesbit M.A., Ashcroft F., Thakker R.V. Mutational analysis of CLC-5, cofilin and CLC-4 in patients with Dent's disease. Nephron Physiol. 2009;112:53-62.
  64. Reinhart S.C., Norden A.G., Lapsley M., Thakker R.V., Pang J., Moses A.M., Frymoyer P.A., Favus M.J., Hoepner J.A., Scheinman S.J. Characterization of carrier females and affected males with X-linked recessive nephrolithiasis. J Am Soc Nephrol. 1995;5:1451-1461.
  65. Gudbjartsson D.F., Holm H., Indridason O.S., Thorleifsson G., Edvardsson V., Sulem P., de Vegt F., d'Ancona F.C., den Heijer M., Wetzels J.F., Franzson L., Rafnar T., Kristjansson K., Bjornsdottir U.S., Eyjolfsson G.I., Kiemeney L.A., Kong A., Palsson R., Thorsteinsdottir U., Stefansson K. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet. 2010;6:e1001039.
  66. Liu C.C., Huang S.P., Tsai L.Y., Wu W.J., Juo S.H., Chou Y.H., Huang C.H., Wu M.T. The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis. Clin Chim Acta. 2010;411:739-743.
  67. Ozturk M., Kordan Y., Cangul H., Dogan H.S., Kilicarslan H., Vuruskan H., Oktay B. Association of urokinase gene 3' -UTR T/C polymorphism with calcium oxalate urolithiasis in children. Int Urol Nephrol. 2008;40:563-568.
  68. Lu X., Gao B., Liu Z., Tian X., Mao X., Emmanuel N., Zhu Q., Xiao C. A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population. Gene. 2012;511:127-130.
  69. Kan W.C., Chou Y.H., Chiu S.J., Hsu Y.W., Lu H.F., Hsu W., Chang W.C. Study of the Association between ITPKC Genetic Polymorphisms and Calcium Nephrolithiasis. Biomed Res Int. 2014;397826:1-6.
  70. Chou Y., Juo S., Chiu Y. A polymorphism of the ORAI1 gene is associated with the risk and recurrence of calcium nephrolithiasis. J Urol. 2011;185:1742-1746.
  71. Аполихин О.И., Сивков А.В., Константинова О.В., Сломинский П.А., Тупицына Т.В., Калиниченко Д.Н. Ассоциация мочекаменной болезни у пациентов с различными состояниями семейного анамнеза по уролитиазу с полиморфизмами его кандидатных генов в российской популяции. Экспериментальная и клиническая урология. 2014;3:50-52.
  72. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М. : ГЭОТАР Медиа. 2016. 496 с.
  73. Coe F.L., Favus M.J., Crockett T, et al. Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med. 1982;72:25-32.
  74. Escribano J., Balaguer A., Roqué i Figuls M., Feliu A., Ferre N. Dietary interventions for preventing complications in idiopathic hypercalciuria. Cochrane Database of Systematic Reviews. 2014;2:CD006022.
  75. Borghi L., Schianchi T., Meschi T., Guerra A., Allegri F., Maggiore U., Novarini A. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. New England Journal of Medicine. 2002;346:77-84.
  76. Pearle M.S., Goldfarb D.S., Assimos D.G., Curhan G., Denu-Ciocca C.J., Matlaga B.R., Monga M., Penniston K.L., Preminger G.M., Turk T.M., White J.R. Medical management of kidney stones: AUA guideline. J Urol. 2014;192:316-324.
  77. Яровой С.К., Москалева Н.Г., Максудов Р.Р. Лекарственная терапия метаболических поражений костного скелета при мочекаменной болезни. Экспериментальная и клиническая урология. 2014;2: 88-93.
  78. Fink H.A., Wilt T.J., Eidman K.E., Garimella P.S., MacDonald R., Rutks I.R., Brasure M., Kane R.L., Ouellette J., Monga M. Medical management to prevent recurrent nephrolithiasiss in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann. Intern. Med. 2013;158:535-543.
  79. Fink H.A., Wilt T.J., Eidman K.E., Garimella P.S., MacDonald R., Rutks I.R., Brasure M., Kane R.L., Monga M. Recurrent Nephrolithiasis in Adults: Comparative Effectiveness of Preventive Medical Strategies. Comparative Effectiveness Review. 2013;61.
  80. Vigen R., Weideman R.A., Reilly R.F. Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? International urology and nephrology. 2011;43:813-819.
  81. Pinheiro V.B., Baxmann A.C., Tiselius H.G. The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. Urology. 2013;82:33-37.
  82. Moseley K.F., Weaver C.M., Appel L., Sebastian A., Sellmeyer D.E. Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women. J. Bone Miner. Res. 2013;28:497-504.
  83. Pak C.Y., Heller H.J., Pearle M.S., Odvina C.V., Poindexter J.R., Peterson R.D. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions J. Urol. 2003;169:465-469.
  84. Sakhaee K., Maalouf M., Sinnott B. Kidney Stones 2012: Pathogenesis, Diagnosis, and Management. The Journal of Clinical Endocrinology and Metabolism. 2012;97:1847-1860.
  85. Giannini S., Nobile M., Dalle Carbonare L., Lodetti M.G., Sella S., Vittadello G., Minicuci N., Crepaldi G. Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. Eur J Endocrinol. 2003;149:209-213.
  86. Heller H.J., Zerwekh J.E., Gottschalk F.A., Pak C.Y. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int. 2007;71:808-815.
  87. Heilberg I.P., Weisinger J.R. Bone disease in idiopathic hypercalciuria. Curr Opin Nephrol Hypertens. 2006;15:394-402.
  88. Vezzoli G., Rubinacci A., Bianchin C., Arcidiacono T., Giambona S., Mignogna G., Fochesato E., Terranegra A., Cusi D., Soldati L. Intestinal calcium absorption is associated with bone mass in stone-forming women with idiopathic hypercalciuria. Am J Kidney Dis. 2003;42:1177-1183.
  89. Bushinsky D.A., Neumann K.J., Asplin J. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999;55:234-243.
  90. Heilberg I.P., Martini L.A., Teixeira S.H., Szejnfeld V.L., Carvalho A.B., Lobao R., Draibe S.A. Effect of Etidronate Treatment on Bone Mass of Male Nephrolithiasis Patients with Idiopathic Hypercalciuria and Osteopenia. Nephron. 1998;79:430-437.
  91. Walton R.J., Russel R.G.G., Smith R. Changes in the renal and extrarenal handling of phosphate induced by sodium etidronate (EHDP) in man. Clin Sci Mol Med. 1975;49:45-56.
  92. Anderson F.H., Francis R.M., Bishop J.C., Rawlings D.J. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. Age Ageing. 1997;26:359-365.
  93. Harris S.T., Watts N.B., Jackson R.D., Genant H.K., Wasnich R.D., Ross P., Miller P.D., Licata A.A., Chesnut C.H. Four year study of intermittent cyclical etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95:557-567.
  94. Arrabal M. The treatment of renal lithiasis with bisphosphonates. Arch. Esp. Urol. 2007;60(9):745-754.
  95. Freundlich M., Alon U.S. Bisphosphonates in children with hypercalciuria and reduced bone mineral density. Pediatr Nephrol. 2008;23:2215-2220.
  96. Giusti A., Barone A., Pioli G., Girasole G., Siccardi V., Palummeri E., Bianchi G. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009;24:1472-1477.
  97. Arrabal-Polo M.A., Arias-Santiago S., de Haro-Muñoz T., Lopez-Ruiz A., Orgaz-Molina J., Gonzalez-Torres S.,Zuluaga-Gomez A., Arrabal-Martin M. Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. Urology. 2013;81:731-737.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies